-
1دورية أكاديمية
المؤلفون: Woff, Erwin, Hendlisz, Alain, Garcia, Camilo, Deleporte, Amélie, Delaunoit, Thierry, Marechal, Raphaël, Holbrechts, S., Van Den Eynde, Marc, Demolin, Gauthier, Vierasu, Irina, Lhommel, Renaud, Gauthier, Namur, Guiot, Thomas, Ameye, Lieveke, Flamen, Patrick
المصدر: European journal of nuclear medicine and molecular imaging, 43 (10
مصطلحات موضوعية: Imagerie médicale, radiologie, tomographie, Adult, Aged, Antineoplastic Combined Chemotherapy Protocols -- administration & dosage, Capecitabine -- administration & dosage, Colorectal Neoplasms -- diagnostic imaging -- drug therapy -- secondary, Drug Monitoring -- methods, Female, Fluorodeoxyglucose F18 -- pharmacokinetics, Humans, Male, Middle Aged, Molecular Targeted Therapy -- methods, Niacinamide -- administration & dosage -- analogs & derivatives, Phenylurea Compounds -- administration & dosage, Positron Emission Tomography Computed Tomography -- methods, Radiopharmaceuticals -- pharmacokinetics, Reproducibility of Results, Sensitivity and Specificity, Sorafenib, Treatment Outcome, Early metabolic response assessment, FDG PET-CT, Metastatic colorectal cancer, Targeted therapy, Tumoral heterogeneity
الوصف: Introduction: The introduction of targeted drugs has had a significant impact on the approach to assessing tumour response. These drugs often induce a rapid cytostatic effect associated with a less pronounced and slower tumoural volume reduction, thereby impairing the correlation between the absence of tumour shrinkage and the patient’s unlikelihood of benefit. The aim of the study was to assess the predictive value of early metabolic response (mR) evaluation after one cycle, and its interlesional heterogeneity to a later metabolic and morphological response assessment performed after three cycles in metastatic colorectal cancer (mCRC) patients treated with combined sorafenib and capecitabine. Methods: This substudy was performed within the framework of a wider prospective multicenter study on the predictive value of early FDG PET-CT response assessment (SoMore study). A lesion-based response analysis was performed, including all measurable lesions identified on the baseline PET. On a per-patient basis, a descriptive 4-class response categorization was applied based upon the presence and proportion of non-responding lesions. For dichotomic response comparison, all patients with at least one resistant lesion were classified as non-responding. Results: On baseline FDG PET-CT, 124 measurable “target” lesions were identified in 38 patients. Early mR assessments showed 18 patients (47 %) without treatment resistant lesions and 12 patients (32 %) with interlesional response heterogeneity. The NPV and PPV of early mR were 85 % (35/41) and 84 % (70/83), respectively, on a per-lesion basis and 95 % (19/20) and 72 % (13/18), respectively, on a dichotomized per-patient basis. Conclusions: Early mR assessment performed after one cycle of sorafenib-capecitabine in mCRC is highly predictive of non-response at a standard response assessment time. The high NPV (95 %) of early mR could be useful as the basis for early treatment discontinuation or adaptation to spare patients from exposure to non-effective drugs. ; SCOPUS: ar.j ...
وصف الملف: 1 full-text file(s): application/pdf
العلاقة: uri/info:doi/10.1007/s00259-016-3365-x; uri/info:pii/10.1007/s00259-016-3365-x; uri/info:pmid/27072811; uri/info:scp/84963685661; uri/info:pmcid/PMC4969337; https://dipot.ulb.ac.be/dspace/bitstream/2013/282990/3/doi_266617.pdfTest; http://hdl.handle.net/2013/ULB-DIPOT:oai:dipot.ulb.ac.be:2013/282990Test
-
2دورية أكاديمية
المؤلفون: Hottinger, A F, Ben Aissa, Assma, Espeli, Vittoria, Squiban, D, Dunkel, Nathalie, Vargas Gomez, Maria Isabel, Hundsberger, T, Mach, Nicolas, Schaller, Karl Lothard, Weber, D C, Bodmer, A, Dietrich, Pierre-Yves
المصدر: ISSN: 0007-0920 ; British journal of cancer, vol. 110, no. 11 (2014) p. 2655-2661.
مصطلحات موضوعية: info:eu-repo/classification/ddc/616.8, info:eu-repo/classification/ddc/616.0757, info:eu-repo/classification/ddc/616, Adult, Aged, Antineoplastic Combined Chemotherapy Protocols/pharmacokinetics/therapeutic use/toxicity, Brain Neoplasms/mortality/therapy, Chemoradiotherapy, Dacarbazine/administration & dosage/analogs & derivatives, Disease-Free Survival, Female, Glioblastoma/mortality/therapy, Humans, Male, Maximum Tolerated Dose, Middle Aged, Niacinamide/administration & dosage/analogs & derivatives, Phenylurea Compounds/administration & dosage, Treatment Outcome
الوصف: Sorafenib (Sb) is a multiple kinase inhibitor targeting both tumour cell proliferation and angiogenesis that may further act as a potent radiosensitizer by arresting cells in the most radiosensitive cell cycle phase. This phase I open-label, noncontrolled dose escalation study was performed to determine the safety and maximum tolerated dose (MTD) of Sb in combination with radiation therapy (RT) and temozolomide (TMZ) in 17 patients with newly diagnosed high-grade glioma.
العلاقة: info:eu-repo/semantics/altIdentifier/pmid/24786603; https://archive-ouverte.unige.ch/unige:90881Test; unige:90881
-
3دورية أكاديمية
المؤلفون: Beuselinck, B, Wolter, P, Karadimou, A, Elaidi, R, Dumez, Herlinde, Rogiers, Annick, Van Cann, T, Willems, L, Body, Jean-Jacques, Berkers, J, Van Poppel, H, Lerut, E, Debruyne, P, Paridaens, R, Schöffski, P
المصدر: British Journal of Cancer, 107 (10
مصطلحات موضوعية: Sciences bio-médicales et agricoles, Antineoplastic Combined Chemotherapy Protocols -- adverse effects -- therapeutic use, Bone Density Conservation Agents -- administration & dosage -- adverse effects, Bone Neoplasms -- drug therapy -- pathology -- secondary, Carcinoma, Renal Cell -- drug therapy -- pathology -- secondary, Diphosphonates -- administration & dosage -- adverse effects, Disease-Free Survival, Female, Humans, Indoles -- administration & dosage, Kidney Neoplasms -- drug therapy -- pathology, Male, Middle Aged, Neoplasm Metastasis, Niacinamide -- administration & dosage -- analogs & derivatives, Osteonecrosis -- chemically induced, Phenylurea Compounds -- administration & dosage, Prognosis, Protein Kinase Inhibitors -- administration & dosage, Protein-Tyrosine Kinases -- antagonists & inhibitors, Pyrroles -- administration & dosage, Retrospective Studies, Treatment Outcome, Bisphosphonates, Bone metastases, Osteonecrosis of the jaw, Outcome, Renal cell carcinoma, Targeted therapy
الوصف: The presence of bone metastases in patients with metastatic renal cell carcinoma treated with oral tyrosine kinase inhibitors (TKIs) is associated with poorer outcome as compared with patients without bone involvement. Concomitant bisphosphonates could probably improve outcomes but also induce osteonecrosis of the jaw (ONJ). ; Journal Article ; Research Support, Non-U.S. Gov't ; SCOPUS: ar.j ; info:eu-repo/semantics/published
وصف الملف: 1 full-text file(s): application/pdf
العلاقة: uri/info:doi/10.1038/bjc.2012.385; uri/info:pii/bjc2012385; uri/info:pmid/23132391; uri/info:scp/84869225968; https://dipot.ulb.ac.be/dspace/bitstream/2013/143043/3/doi_126664.pdfTest; http://hdl.handle.net/2013/ULB-DIPOT:oai:dipot.ulb.ac.be:2013/143043Test
-
4
المؤلفون: Pierre Laurent-Puig, Sylvain Poujol, Françoise Desseigne, S. Thezenas, Thibault Mazard, Evelyne Crapez, Emmanuelle Samalin, E. Francois, Antoine Adenis, T. Conroy, J.F. Seitz, Julien Taieb, M.P. Galais, Jaafar Bennouna, F. Boissière, Marc Ychou, Eric Assenat, O. Bouche, Frédéric Bibeau
المساهمون: CRLCC Val d'Aurelle - Paul Lamarque, Hôpital universitaire Robert Debré [Reims], Centre de Lutte contre le Cancer Antoine Lacassagne [Nice] (UNICANCER/CAL), UNICANCER-Université Côte d'Azur (UCA), Centre Régional de Lutte contre le Cancer Oscar Lambret [Lille] (UNICANCER/Lille), Université de Lille-UNICANCER, Institut de Cancérologie de l'Ouest [Angers/Nantes] (UNICANCER/ICO), UNICANCER, CIC - HEGP (CIC 1418), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Européen Georges Pompidou [APHP] (HEGP), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO)-Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM), Centre Léon Bérard [Lyon], Hôpital de la Timone [CHU - APHM] (TIMONE), Institut de Cancérologie de Lorraine - Alexis Vautrin [Nancy] (UNICANCER/ICL), Centre Régional de Lutte contre le Cancer François Baclesse [Caen] (UNICANCER/CRLC), Normandie Université (NU)-UNICANCER-Tumorothèque de Caen Basse-Normandie (TCBN), Institut de Génétique Moléculaire de Montpellier (IGMM), Université de Montpellier (UM)-Centre National de la Recherche Scientifique (CNRS), Institut de recherche en cancérologie de Montpellier (IRCM - U896 Inserm - UM1), Université Montpellier 1 (UM1)-CRLCC Val d'Aurelle - Paul Lamarque-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Montpellier (UM), CRLC Val d'Aurelle-Paul Lamarque, Hôpital Européen Georges Pompidou [APHP] (HEGP), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO), Université Lille Nord de France (COMUE)-UNICANCER, UNICANCER-Tumorothèque de Caen Basse-Normandie (TCBN)-Normandie Université (NU), Centre National de la Recherche Scientifique (CNRS)-Université de Montpellier (UM), CRLCC Val d'Aurelle - Paul Lamarque-Université de Montpellier (UM)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Montpellier 1 (UM1), Institut de Recherche en Cancérologie de Montpellier (IRCM - U1194 Inserm - UM), CRLCC Val d'Aurelle - Paul Lamarque-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Montpellier (UM), Centre Antoine Lacassagne, CRLCC Antoine Lacassagne, CRLCC Oscar Lambret, Institut de Cancérologie de l'Ouest, Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-Hôpital Européen Georges Pompidou [APHP] (HEGP), Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO)-Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO)-Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM), Institut de Cancérologie de Lorraine - Alexis Vautrin (ICL), Centre Régional de Lutte contre le Cancer François Baclesse (CRLC François Baclesse ), Normandie Université (NU)-Tumorothèque de Caen Basse-Normandie (TCBN), Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO)-Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)
المصدر: British Journal of Cancer
Breast Cancer Research and Treatment
Breast Cancer Research and Treatment, 2014, 110, pp.1148--54. ⟨10.1038/bjc.2013.813⟩
Breast Cancer Research and Treatment, Springer Verlag, 2014, 110, pp.1148--54. ⟨10.1038/bjc.2013.813⟩مصطلحات موضوعية: Male, Cancer Research, Colorectal cancer, medicine.medical_treatment, Camptothecin/administration & dosage/analogs & derivatives, Gastroenterology, tyrosine kinase inhibitor, Antineoplastic Combined Chemotherapy Protocols, Clinical endpoint, 80 and over, clinic, Aged, 80 and over, education.field_of_study, metastatic colorectal cancer, ras Proteins/*genetics, Mutation, Middle Aged, Sorafenib, 3. Good health, Oncology, Disease Progression, Female, Colorectal Neoplasms, medicine.drug, Adult, Niacinamide, medicine.medical_specialty, Niacinamide/administration & dosage/analogs & derivatives, Population, Colorectal Neoplasms/*drug therapy/genetics, [SDV.CAN]Life Sciences [q-bio]/Cancer, Neutropenia, Irinotecan, Disease-Free Survival, Proto-Oncogene Proteins p21(ras), Internal medicine, Proto-Oncogene Proteins, medicine, Humans, Antineoplastic Combined Chemotherapy Protocols/*therapeutic use, education, neoplasms, Aged, Chemotherapy, business.industry, Phenylurea Compounds, medicine.disease, digestive system diseases, Surgery, KRAS gene mutation, Regimen, Phenylurea Compounds/administration & dosage, Clinical Study, ras Proteins, Proto-Oncogene Proteins/*genetics, Camptothecin, business
الوصف: IMPACT: 5.922; International audience; BACKGROUND: This trial evaluated the feasibility and efficacy of combined sorafenib and irinotecan (NEXIRI) as second- or later-line treatment of patients with KRAS-mutated metastatic colorectal cancer (mCRC), who had progressed after irinotecan-based chemotherapy. METHODS: In Phase I, in a 3+3 dose escalation schedule, patients received irinotecan (125, 150 or 180 mg m(-2) every 2 weeks), in combination with 400 mg sorafenib b.d. The primary end point was the maximum-tolerated dose of irinotecan. In Phase II, the primary end point was disease control rate (DCR). Secondary end points were progression-free survival (PFS), overall survival (OS) and toxicity. RESULTS: Phase I included 10 patients (median age 63 (49-73)); no dose-limiting toxicity was seen. In Phase II, 54 patients (median age 60 (43-80) years) received irinotecan 180 mg m(-)(2) every 2 weeks with sorafenib 400 mg b.d. Nine patients (17%) remained on full-dose sorafenib. The DCR was 64.9% (95% CI, 51-77). Median PFS and OS were 3.7 (95% CI, 3.2-4.7) and 8.0 (95% CI, 4.8-9.7) months, respectively. Toxicities included Grade 3 diarrhoea (37%), neutropenia (18%), hand-foot syndrome (13%) and Grade 4 neutropenia (17%). CONCLUSION: The NEXIRI regimen showed promising activity as second- or later-line treatment in this heavily pretreated mCRC population (ClinicalTrials.gov NCT00989469).
الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0de27d5b42bd45149c4970a8cb5a2512Test
http://europepmc.org/articles/PMC3950852Test -
5
المؤلفون: Lieveke Ameye, Raphaël Maréchal, Amélie Deleporte, Irina Vierasu, Erwin Woff, Thomas Guiot, Camilo Garcia, Alain Hendlisz, Thierry Delaunoit, Gauthier Demolin, Namur Gauthier, Renaud Lhommel, Patrick Flamen, Marc Van den Eynde, Stéphane Holbrechts
المساهمون: UCL - SSS/IREC/MIRO - Pôle d'imagerie moléculaire, radiothérapie et oncologie, UCL - (SLuc) Service de médecine nucléaire, UCL - (SLuc) Unité d'oncologie médicale, UCL - (SLuc) Centre du cancer
المصدر: European Journal of Nuclear Medicine and Molecular Imaging
European Journal of Nuclear Medicine and Molecular Imaging, Vol. 43, p. 1792-1801 (2016)
European journal of nuclear medicine and molecular imaging, 43 (10مصطلحات موضوعية: Oncology, Male, Colorectal cancer, medicine.medical_treatment, Phenylurea Compounds -- administration & dosage, 030218 nuclear medicine & medical imaging, Targeted therapy, Tumoral heterogeneity, 0302 clinical medicine, Positron Emission Tomography Computed Tomography, Antineoplastic Combined Chemotherapy Protocols, Radiopharmaceuticals -- pharmacokinetics, Molecular Targeted Therapy, Fluorodeoxyglucose F18 -- pharmacokinetics, Imagerie médicale, radiologie, tomographie, Metastatic colorectal cancer, Colorectal Neoplasms -- diagnostic imaging -- drug therapy -- secondary, General Medicine, Middle Aged, Sorafenib, Treatment Outcome, Drug Monitoring -- methods, Radiology Nuclear Medicine and imaging, 030220 oncology & carcinogenesis, Fdg pet ct, Female, Original Article, Niacinamide -- administration & dosage -- analogs & derivatives, medicine.symptom, Drug Monitoring, Colorectal Neoplasms, medicine.drug, Adult, Niacinamide, medicine.medical_specialty, Sensitivity and Specificity, Capecitabine, Lesion, FDG PET-CT, 03 medical and health sciences, Fluorodeoxyglucose F18, Internal medicine, medicine, Volume reduction, Humans, Molecular Targeted Therapy -- methods, Radiology, Nuclear Medicine and imaging, Aged, business.industry, Phenylurea Compounds, Reproducibility of Results, Positron Emission Tomography Computed Tomography -- methods, medicine.disease, Capecitabine -- administration & dosage, Discontinuation, Antineoplastic Combined Chemotherapy Protocols -- administration & dosage, Radiopharmaceuticals, business, Early metabolic response assessment
الوصف: Introduction: The introduction of targeted drugs has had a significant impact on the approach to assessing tumour response. These drugs often induce a rapid cytostatic effect associated with a less pronounced and slower tumoural volume reduction, thereby impairing the correlation between the absence of tumour shrinkage and the patient’s unlikelihood of benefit. The aim of the study was to assess the predictive value of early metabolic response (mR) evaluation after one cycle, and its interlesional heterogeneity to a later metabolic and morphological response assessment performed after three cycles in metastatic colorectal cancer (mCRC) patients treated with combined sorafenib and capecitabine. Methods: This substudy was performed within the framework of a wider prospective multicenter study on the predictive value of early FDG PET-CT response assessment (SoMore study). A lesion-based response analysis was performed, including all measurable lesions identified on the baseline PET. On a per-patient basis, a descriptive 4-class response categorization was applied based upon the presence and proportion of non-responding lesions. For dichotomic response comparison, all patients with at least one resistant lesion were classified as non-responding. Results: On baseline FDG PET-CT, 124 measurable “target” lesions were identified in 38 patients. Early mR assessments showed 18 patients (47 %) without treatment resistant lesions and 12 patients (32 %) with interlesional response heterogeneity. The NPV and PPV of early mR were 85 % (35/41) and 84 % (70/83), respectively, on a per-lesion basis and 95 % (19/20) and 72 % (13/18), respectively, on a dichotomized per-patient basis. Conclusions: Early mR assessment performed after one cycle of sorafenib-capecitabine in mCRC is highly predictive of non-response at a standard response assessment time. The high NPV (95 %) of early mR could be useful as the basis for early treatment discontinuation or adaptation to spare patients from exposure to non-effective drugs.
SCOPUS: ar.j
info:eu-repo/semantics/publishedوصف الملف: 1 full-text file(s): application/pdf
الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3e0aa1f3a5363635b991f75146123099Test
https://pubmed.ncbi.nlm.nih.gov/27072811Test -
6دورية أكاديمية
المؤلفون: Samalin, E., Bouche, O., Thezenas, S., Francois, E., Adenis, Antoine, Bennouna, J., Taieb, J., Desseigne, Françoise, Seitz, J. F., Conroy, T., Galais, M. P., Assenat, Eric, Crapez, Evelyne, Poujol, Sylvain, Bibeau, Frédéric, Boissiere, F., Laurent-Puig, P., Ychou, Marc, Mazard, Thibault
المساهمون: CRLCC Val d'Aurelle - Paul Lamarque, Hôpital universitaire Robert Debré Reims (CHU Reims), Centre de Lutte contre le Cancer Antoine Lacassagne Nice (UNICANCER/CAL), UNICANCER-Université Côte d'Azur (UniCA), Centre Régional de Lutte contre le Cancer Oscar Lambret Lille (UNICANCER/Lille), Université de Lille-UNICANCER, Institut de Cancérologie de l'Ouest Angers/Nantes (UNICANCER/ICO), UNICANCER, CIC - HEGP (CIC 1418), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Européen Georges Pompidou APHP (HEGP), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO)-Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM), Centre Léon Bérard Lyon, Hôpital de la Timone CHU - APHM (TIMONE), Institut de Cancérologie de Lorraine - Alexis Vautrin Nancy (UNICANCER/ICL), Centre Régional de Lutte contre le Cancer François Baclesse Caen (UNICANCER/CRLC), Normandie Université (NU)-UNICANCER-Tumorothèque de Caen Basse-Normandie (TCBN), Institut de Génétique Moléculaire de Montpellier (IGMM), Université de Montpellier (UM)-Centre National de la Recherche Scientifique (CNRS), Institut de recherche en cancérologie de Montpellier (IRCM - U896 Inserm - UM1), Université Montpellier 1 (UM1)-CRLCC Val d'Aurelle - Paul Lamarque-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Montpellier (UM), CRLC Val d'Aurelle-Paul Lamarque, Hôpital Européen Georges Pompidou APHP (HEGP), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO)
المصدر: ISSN: 0167-6806.
مصطلحات موضوعية: Humans, Female, Middle Aged, Adult, Male, Aged, 80 and over, Proto-Oncogene Proteins/*genetics, ras Proteins/*genetics, Disease-Free Survival, clinic, Disease Progression, Antineoplastic Combined Chemotherapy Protocols/*therapeutic use, Mutation, Camptothecin/administration & dosage/analogs & derivatives, Colorectal Neoplasms/*drug therapy/genetics, Niacinamide/administration & dosage/analogs & derivatives, Phenylurea Compounds/administration & dosage, [SDV.CAN]Life Sciences [q-bio]/Cancer
الوصف: IMPACT: 5.922 ; International audience ; BACKGROUND: This trial evaluated the feasibility and efficacy of combined sorafenib and irinotecan (NEXIRI) as second- or later-line treatment of patients with KRAS-mutated metastatic colorectal cancer (mCRC), who had progressed after irinotecan-based chemotherapy. METHODS: In Phase I, in a 3+3 dose escalation schedule, patients received irinotecan (125, 150 or 180 mg m(-2) every 2 weeks), in combination with 400 mg sorafenib b.d. The primary end point was the maximum-tolerated dose of irinotecan. In Phase II, the primary end point was disease control rate (DCR). Secondary end points were progression-free survival (PFS), overall survival (OS) and toxicity. RESULTS: Phase I included 10 patients (median age 63 (49-73)); no dose-limiting toxicity was seen. In Phase II, 54 patients (median age 60 (43-80) years) received irinotecan 180 mg m(-)(2) every 2 weeks with sorafenib 400 mg b.d. Nine patients (17%) remained on full-dose sorafenib. The DCR was 64.9% (95% CI, 51-77). Median PFS and OS were 3.7 (95% CI, 3.2-4.7) and 8.0 (95% CI, 4.8-9.7) months, respectively. Toxicities included Grade 3 diarrhoea (37%), neutropenia (18%), hand-foot syndrome (13%) and Grade 4 neutropenia (17%). CONCLUSION: The NEXIRI regimen showed promising activity as second- or later-line treatment in this heavily pretreated mCRC population (ClinicalTrials.gov NCT00989469).
العلاقة: info:eu-repo/semantics/altIdentifier/pmid/24407191; hal-02181353; https://hal.umontpellier.fr/hal-02181353Test; PUBMED: 24407191; PUBMEDCENTRAL: PMC3950852
-
7
المؤلفون: Thomas Hundsberger, Dietrich Py, N. Dunkel, A. Ben Aissa, Maria Vargas, Andreas F. Hottinger, Karl Lothard Schaller, Vittoria Espeli, Nicolas Mach, D. Squiban, Damien C. Weber, A Bodmer
المصدر: British Journal of Cancer, vol. 110, no. 11, pp. 2655-2661
British Journal of Cancer
British Journal of Cancer, Vol. 110, No 11 (2014) pp. 2655-2661مصطلحات موضوعية: Oncology, Male, Cancer Research, medicine.medical_treatment, Pharmacology, urologic and male genital diseases, radiation therapy, tyrosine kinase inhibitor, Antineoplastic Combined Chemotherapy Protocols, heterocyclic compounds, ddc:616, Glioblastoma/mortality/therapy, Brain Neoplasms, Chemoradiotherapy, Middle Aged, Sorafenib, Brain Neoplasms/mortality/therapy, female genital diseases and pregnancy complications, Phase i study, Dacarbazine, Treatment Outcome, Female, Corrigendum, high-grade glioma, medicine.drug, Adult, Niacinamide, medicine.medical_specialty, Niacinamide/administration & dosage/analogs & derivatives, Maximum Tolerated Dose, ddc:616.0757, pharmacokinetic study, Disease-Free Survival, Glioma, Internal medicine, medicine, Temozolomide, Humans, neoplasms, Aged, business.industry, Phenylurea Compounds, medicine.disease, digestive system diseases, ddc:616.8, First line treatment, Radiation therapy, Phenylurea Compounds/administration & dosage, Clinical Study, Antineoplastic Combined Chemotherapy Protocols/pharmacokinetics/therapeutic use/toxicity, Dacarbazine/administration & dosage/analogs & derivatives, business, Glioblastoma
الوصف: BACKGROUND: Sorafenib (Sb) is a multiple kinase inhibitor targeting both tumour cell proliferation and angiogenesis that may further act as a potent radiosensitizer by arresting cells in the most radiosensitive cell cycle phase. This phase I open-label, noncontrolled dose escalation study was performed to determine the safety and maximum tolerated dose (MTD) of Sb in combination with radiation therapy (RT) and temozolomide (TMZ) in 17 patients with newly diagnosed high-grade glioma. METHODS: Patients were treated with RT (60 Gy in 2 Gy fractions) combined with TMZ 75 mg m(-2) daily, and Sb administered at three dose levels (200 mg daily, 200 mg BID, and 400 mg BID) starting on day 8 of RT. Thirty days after the end of RT, patients received monthly TMZ (150-200 mg m(-2) D1-5/28) and Sb (400 mg BID). Pharmacokinetic (PK) analyses were performed on day 8 (TMZ) and on day 21 (TMZ&Sb) (Clinicaltrials ID: NCT00884416). RESULTS: The MTD of Sb was established at 200 mg BID. Dose-limiting toxicities included thrombocytopenia (two patients), diarrhoea (one patient) and hypercholesterolaemia (one patient). Sb administration did not affect the mean area under the curve(0-24) and mean Cmax of TMZ and its metabolite 5-amino-imidazole-4-carboxamide (AIC). Tmax of both TMZ and AIC was delayed from 0.75 (TMZ alone) to 1.5 h (combined TMZ/Sb). The median progression-free survival was 7.9 months (95% confidence interval (CI): 5.4-14.55), and the median overall survival was 17.8 months (95% CI: 14.7-25.6). CONCLUSIONS: Although Sb can be combined with RT and TMZ, significant side effects and moderate outcome results do not support further clinical development in malignant gliomas. The robust PK data of the TMZ/Sb combination could be useful in other cancer settings.
وصف الملف: application/pdf
الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5769967950cf20f0072e4f151af7bd83Test
https://serval.unil.ch/resource/serval:BIB_A3EE92645B9C.P001/REF.pdfTest -
8
المؤلفون: Pascal Wolter, Alexandra Karadimou, Jean-Jacques Body, Patrick Schöffski, H. Van Poppel, Ludo Willems, Benoit Beuselinck, Philip R. Debruyne, Annick Rogiers, T. van Cann, R. Elaidi, Robert Paridaens, Herlinde Dumez, Joost Berkers, Evelyne Lerut
المصدر: British Journal of Cancer
British Journal of Cancer, 107 (10مصطلحات موضوعية: Male, Cancer Research, Pathology, Diphosphonates -- administration & dosage -- adverse effects, Indoles, Phenylurea Compounds -- administration & dosage, Antineoplastic Combined Chemotherapy Protocols -- adverse effects -- therapeutic use, Targeted therapy, bone metastases, Renal cell carcinoma, Antineoplastic Combined Chemotherapy Protocols, Bone Density Conservation Agents -- administration & dosage -- adverse effects, Bone Neoplasms -- drug therapy -- pathology -- secondary, Sunitinib, Neoplasm Metastasis, Indoles -- administration & dosage, Outcome, Bone Density Conservation Agents, Diphosphonates, Protein Kinase Inhibitors -- administration & dosage, Osteonecrosis, Bisphosphonates, Sciences bio-médicales et agricoles, Middle Aged, Protein-Tyrosine Kinases, Sorafenib, Prognosis, targeted therapy, Kidney Neoplasms, Treatment Outcome, Oncology, outcome, Female, Niacinamide -- administration & dosage -- analogs & derivatives, Tyrosine kinase, medicine.drug, Carcinoma, Renal Cell -- drug therapy -- pathology -- secondary, Niacinamide, medicine.medical_specialty, renal cell carcinoma, Bone Neoplasms, Osteonecrosis -- chemically induced, Disease-Free Survival, Kidney Neoplasms -- drug therapy -- pathology, Pyrroles -- administration & dosage, medicine, Carcinoma, Humans, Pyrroles, Carcinoma, Renal Cell, Protein Kinase Inhibitors, bisphosphonates, Retrospective Studies, Osteonecrosis of the jaw, business.industry, Protein-Tyrosine Kinases -- antagonists & inhibitors, Bone metastases, Phenylurea Compounds, medicine.disease, osteonecrosis of the jaw, Concomitant, Cancer research, Clinical Study, business
الوصف: The presence of bone metastases in patients with metastatic renal cell carcinoma treated with oral tyrosine kinase inhibitors (TKIs) is associated with poorer outcome as compared with patients without bone involvement. Concomitant bisphosphonates could probably improve outcomes but also induce osteonecrosis of the jaw (ONJ).
Journal Article
Research Support, Non-U.S. Gov't
SCOPUS: ar.j
info:eu-repo/semantics/publishedوصف الملف: 1 full-text file(s): application/pdf
الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cdb22c4137af4f142fa2a48d0882b042Test
https://pubmed.ncbi.nlm.nih.gov/23132391Test -
9دورية أكاديمية
المؤلفون: Suryapranata, H. (Harry), Serruys, P.W.J.C. (Patrick), Feyter, P.J. (Pim) de, Verdouw, P.D. (Pieter), Hugenholtz, P.G. (Paul)
المصدر: The American Journal of Cardiology vol. 61, pp. 292-297
مصطلحات موضوعية: 0 (Vasodilator Agents), 65141-46-0 (Nicorandil), 98-92-0 (Niacinamide), Adult, Aged, Blood Pressure/drug effects, Coronary Angiography, Coronary Circulation/drug effects, Coronary Disease/physiopathology, Coronary Vessels/*drug effects/physiopathology, Female, Human, Male, Middle Aged, Myocardium/metabolism, Niacinamide/administration & dosage/*analogs & derivatives/pharmacology, Nicorandil, Oxygen Consumption/drug effects, Vascular Resistance/drug effects, Vasodilation/*drug effects, Vasodilator Agents/*administration & dosage/pharmacology
الوصف: Coronary hemodynamics and vasodilatory effects on major epicardial arteries were investigated after a single dose of nicorandil in 22 patients undergoing cardiac catheterization for suspected coronary artery disease. Nicorandil, 20 mg, was administered sublingually to 11 consecutive patients and 40 mg to 11 others. Systemic blood pressure decreased significantly without affecting the heart rate. Coronary sinus blood flow did not change significantly. As the mean aortic pressure decreased significantly by 13% after 20 mg and 21% after 40 mg of nicorandil, the calculated coronary vascular resistance decreased but did not reach statistical significance. There was a decrease in myocardial oxygen consumption (-14% and -22%, respectively), and this was consistent with a significant decrease in the calculated pressure-rate product of 19% and 24%, respectively. A total of 103 selected coronary segments, including 17 stenotic segments, were analyzed quantitatively using a computer-assisted coronary angiography analysis system. After 20 or 40 mg of nicorandil, a significant increase of the mean diameter was observed in the proximal (+9% and +7%), midportion (+10% and +11%) and distal (+15% and +13%) parts of the left anterior descending coronary artery. Corresponding values for the proximal (+13% and +10%) and distal (+10% and +15%) segments of the circumflex artery were observed. An increase in the obstruction diameter was also observed in all but 3 of the analyzed stenotic segments. The results demonstrate that nicorandil, in the route and doses used, causes a significant vasodilation in the major epicardial coronary segments, including most stenotic segments, and decreases the myocardial oxygen demand with little effect on the resistance vessels.
وصف الملف: application/pdf
العلاقة: http://repub.eur.nl/pub/4277Test; urn:hdl:1765/4277
الإتاحة: http://repub.eur.nl/pub/4277Test
-
10مورد إلكتروني
المصدر: European journal of nuclear medicine and molecular imaging, 43 (10
مستخلص: Introduction: The introduction of targeted drugs has had a significant impact on the approach to assessing tumour response. These drugs often induce a rapid cytostatic effect associated with a less pronounced and slower tumoural volume reduction, thereby impairing the correlation between the absence of tumour shrinkage and the patient’s unlikelihood of benefit. The aim of the study was to assess the predictive value of early metabolic response (mR) evaluation after one cycle, and its interlesional heterogeneity to a later metabolic and morphological response assessment performed after three cycles in metastatic colorectal cancer (mCRC) patients treated with combined sorafenib and capecitabine. Methods: This substudy was performed within the framework of a wider prospective multicenter study on the predictive value of early FDG PET-CT response assessment (SoMore study). A lesion-based response analysis was performed, including all measurable lesions identified on the baseline PET. On a per-patient basis, a descriptive 4-class response categorization was applied based upon the presence and proportion of non-responding lesions. For dichotomic response comparison, all patients with at least one resistant lesion were classified as non-responding. Results: On baseline FDG PET-CT, 124 measurable “target” lesions were identified in 38 patients. Early mR assessments showed 18 patients (47 %) without treatment resistant lesions and 12 patients (32 %) with interlesional response heterogeneity. The NPV and PPV of early mR were 85 % (35/41) and 84 % (70/83), respectively, on a per-lesion basis and 95 % (19/20) and 72 % (13/18), respectively, on a dichotomized per-patient basis. Conclusions: Early mR assessment performed after one cycle of sorafenib-capecitabine in mCRC is highly predictive of non-response at a standard response assessment time. The high NPV (95 %) of early mR could be useful as the basis for early treatment discontinuation or adaptation to spare patients from ex
SCOPUS: ar.j
info:eu-repo/semantics/publishedمصطلحات الفهرس: Imagerie médicale, radiologie, tomographie, Adult, Aged, Antineoplastic Combined Chemotherapy Protocols -- administration & dosage, Capecitabine -- administration & dosage, Colorectal Neoplasms -- diagnostic imaging -- drug therapy -- secondary, Drug Monitoring -- methods, Female, Fluorodeoxyglucose F18 -- pharmacokinetics, Humans, Male, Middle Aged, Molecular Targeted Therapy -- methods, Niacinamide -- administration & dosage -- analogs & derivatives, Phenylurea Compounds -- administration & dosage, Positron Emission Tomography Computed Tomography -- methods, Radiopharmaceuticals -- pharmacokinetics, Reproducibility of Results, Sensitivity and Specificity, Sorafenib, Treatment Outcome, Early metabolic response assessment, FDG PET-CT, Metastatic colorectal cancer, Targeted therapy, Tumoral heterogeneity, info:eu-repo/semantics/article, info:ulb-repo/semantics/articlePeerReview, info:ulb-repo/semantics/openurl/article
